Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume.
Icodextrin 7.5% is an isosmolar solution for once-daily use in peritoneal dialysis for patients with end-stage renal failure (ESRF). It produces substantial ultrafiltration (UF), performing best over longer dwells of 8-12 h in continuous ambulatory peritoneal dialysis (CAPD) patients, and up to 16 h in automated peritoneal dialysis (APD) patients. Subsequent use in other clinical areas (ultrafiltration failure) and normal postmarketing clinical experience has established its tolerability and safety profiles; a small number of patients, including those with diabetes, have now received icodextrin for up to 6 years. Icodextrin's ability to maintain intraperitoneal volume over many hours has led to its undergoing development as an intraperitoneal drug delivery system for targeted regional delivery of anticancer drugs and lymphatic delivery of anti-HIV treatment. Isosmolar icodextrin 7.5% solution represents the first major advance in the treatment of ESRF by peritoneal dialysis since the development of CAPD using glucose-based solutions 20 years ago.
Peers
E
E
ML Laboratories plc, Blaby, Leicester, UK.
Gokal
R
R
D015314:Dialysis Solutions; D005936:Glucans; D005947:Glucose; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000628:therapy*; D015337:Multicenter Studies as Topic; D009994:Osmolar Concentration; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D016032:Randomized Controlled Trials as Topic
D015314:Dialysis Solutions; D005936:Glucans; D000077607:Icodextrin; D005947:Glucose